Soleno Therapeutics Inc

SLNO

Company Profile

  • Business description

    Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

  • Contact

    100 Marine Parkway
    Suite 400
    Redwood CityCA94065
    USA

    T: +1 650 213-8444

    E: [email protected]

    https://www.soleno.life

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    152

Stocks News & Analysis

stocks

Continuing problems at the ASX

Interim report by financial regulator is a hit to sentiment.
stocks

Top investing lessons from 2025

13 lessons from Morningstar’s James Gruber.
stocks

Chart of the Week: Aussie dividend yields are less attractive than alternatives

The latest insights from our equity research team.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.7032.600.37%
CAC 408,121.3535.300.44%
DAX 4024,096.39135.800.57%
Dow JONES (US)48,211.67325.700.68%
FTSE 1009,782.157.830.08%
HKSE25,498.1329.350.12%
NASDAQ23,026.72333.401.47%
Nikkei 22549,001.50510.78-1.03%
NZX 50 Index13,256.7739.14-0.29%
S&P 5006,789.0167.581.01%
S&P/ASX 2008,588.2031.700.37%
SSE Composite Index3,876.376.090.16%

Market Movers